Back to Newsroom

Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss

Zug, Switzerland, Feb. 24, 2017 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for AM-111 in the treatment of acute sensorineural (inner ear) hearing loss (ASNHL).

Click here to read the full release